Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Coronavirus COVID-19 Clinical Trials

Samsung Bioepis Begins Denosumab Trials

Company Also Announces Successful Ranibizumab Phase III Trials And US Filing

  • News

Executive Summary

Samsung Bioepis has announced that its Prolia/Xgeva (denosumab) biosimilar, SB16, has begun Phase I clinical trials. Further, the company’s Lucentis (ranibizumab) biosimilar, SB11, has produced positive Phase III data and has been filed in the US. Meanwhile, CEO and president Christopher Hansung Ko has commented on the impact of the coronavirus pandemic on the industry and competition from domestic companies in the Chinese market. 

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Coronavirus COVID-19 Clinical Trials
Latest Headlines

Biocon Strikes Mexican Deal For Liraglutide

A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets

Xbrane Pulls In US Ranibizumab Partner After FDA Disappointment

Celltrion Offers 85% Discount For Adalimumab Biosimilar In US

See All
UsernamePublicRestriction

Register

GB150450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By